Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2012, Article ID 172897, 9 pages
http://dx.doi.org/10.1155/2012/172897
Review Article

Fenretinide (4-HPR): A Preventive Chance for Women at Genetic and Familial Risk?

Division of Cancer Prevention and Genetics, European Institute of Oncology, 20141 Milan, Italy

Received 5 October 2011; Revised 12 December 2011; Accepted 15 December 2011

Academic Editor: Dianne R. Soprano

Copyright © 2012 Massimiliano Cazzaniga et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Chambon, “A decade of molecular biology of retinoic acid receptors,” FASEB Journal, vol. 10, no. 9, pp. 940–954, 1996. View at Google Scholar · View at Scopus
  2. F. Rehman, P. Shanmugasundaram, and M. P. Schrey, “Fenretinide stimulates redox-sensitive ceramide production in breast cancer cells: potential role in drug-induced cytotoxicity,” British Journal of Cancer, vol. 91, no. 10, pp. 1821–1828, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. S. Y. Sun and R. Lotan, “Retinoids and their receptors in cancer development and chemoprevention,” Critical Reviews in Oncology/Hematology, vol. 41, no. 1, pp. 41–55, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Decensi, H. Johansson, R. Miceli et al., “Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 10, no. 10, pp. 1047–1053, 2001. View at Google Scholar · View at Scopus
  5. Z. S. Gucev, Y. Oh, K. M. Kelley, and R. G. Rosenfeld, “Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor β2-induced growth inhibition in human breast cancer cells,” Cancer Research, vol. 56, no. 7, pp. 1545–1550, 1996. View at Google Scholar · View at Scopus
  6. I. Nunes, S. Kojima, and D. B. Rifkin, “Effects of endogenously activated transforming growth factor-β on growth and differentiation of retinoic acid-treated HL-60 cells,” Cancer Research, vol. 56, no. 3, pp. 495–499, 1996. View at Google Scholar · View at Scopus
  7. M. Pfahl, “Nuclear receptor/AP-1 interaction,” Endocrine Reviews, vol. 14, no. 5, pp. 651–658, 1993. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Dedieu and P. Lefebvre, “Retinoids interfere with the AP1 signalling pathway in human breast cancer cells,” Cellular Signalling, vol. 18, no. 6, pp. 889–898, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. R. C. Moon, D. L. McCormick, and R. G. Mehta, “Inhibition of carcinogenesis by retinoids,” Cancer Research, vol. 43, no. 5, pp. 2469–2475, 1983. View at Google Scholar · View at Scopus
  10. M. A. Anzano, S. W. Byers, J. M. Smith et al., “Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen,” Cancer Research, vol. 54, no. 17, pp. 4614–4617, 1994. View at Google Scholar · View at Scopus
  11. M. A. Anzano, C. W. Peer, J. M. Smith et al., “Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid,” Journal of the National Cancer Institute, vol. 88, no. 2, pp. 123–125, 1996. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Wu, H. T. Kim, J. L. Rodriquez et al., “Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069,” Cancer Epidemiology Biomarkers and Prevention, vol. 11, no. 5, pp. 467–474, 2002. View at Google Scholar · View at Scopus
  13. K. Wu, H. T. Kim, J. L. Rodriquez et al., “9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice,” Clinical Cancer Research, vol. 6, no. 9, pp. 3696–3704, 2000. View at Google Scholar · View at Scopus
  14. K. Wu, Y. Zhang, X. C. Xu et al., “The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice,” Cancer Research, vol. 62, no. 22, pp. 6376–6380, 2002. View at Google Scholar · View at Scopus
  15. M. M. Gottardis, E. D. Bischoff, M. A. Shirley, M. A. Wagoner, W. W. Lamph, and R. A. Heyman, “Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR- selective ligand,” Cancer Research, vol. 56, no. 24, pp. 5566–5570, 1996. View at Google Scholar · View at Scopus
  16. S. Y. Sun, W. Li, P. Yue, S. M. Lippman, W. K. Hong, and R. Lotan, “Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms,” Cancer Research, vol. 59, no. 10, pp. 2493–2498, 1999. View at Google Scholar · View at Scopus
  17. M. S. Sheikh, Z. M. Shao, X. S. Li et al., “N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma,” Carcinogenesis, vol. 16, no. 10, pp. 2477–2486, 1995. View at Google Scholar · View at Scopus
  18. A. N. Fanjul, D. Delia, M. A. Pierotti, D. Rideout, J. Q. Qiu, and M. Pfahl, “4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors,” Journal of Biological Chemistry, vol. 271, no. 37, pp. 22441–22446, 1996. View at Publisher · View at Google Scholar · View at Scopus
  19. V. Giandomenico, F. Andreola, M. L. Rodriguez de la Concepcion, S. J. Collins, and L. M. de Luca, “Retinoic acid and 4-hydroxyphenylretinamide induce growth inhibition and tissue transglutaminase through different signal transduction pathways in mouse fibroblasts (NIH 3T3 cells),” Carcinogenesis, vol. 20, no. 6, pp. 1133–1135, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. A. L. Anding, J. S. Chapman, D. W. Barnett, R. W. Curley Jr., and M. Clagett-Dame, “The unhydrolyzable fenretinide analogue 4-hydroxybenzylretinone induces the proapoptotic genes GADD153 (CHOP) and Bcl-2-binding component 3 (PUMA) and apoptosis that is caspase-dependent and independent of the retinoic acid receptor,” Cancer Research, vol. 67, no. 13, pp. 6270–6277, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. D. D'Elia, A. Aiello, L. Lombardi et al., “N-(4-Hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid,” Cancer Research, vol. 53, no. 24, pp. 6036–6041, 1993. View at Google Scholar · View at Scopus
  22. R. Lotan, “Retinoids and apoptosis: implications for cancer chemoprevention and therapy,” Journal of the National Cancer Institute, vol. 87, no. 22, pp. 1655–1657, 1995. View at Google Scholar · View at Scopus
  23. W. F. Holmes, D. R. Soprano, and K. J. Soprano, “Comparison of the mechanism of induction of apoptosis in ovarian carcinoma cells by the conformationally restricted synthetic retinoids CD437 and 4-HPR,” Journal of Cellular Biochemistry, vol. 89, no. 2, pp. 262–278, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. W. F. Holmes, D. R. Soprano, and K. J. Soprano, “Synthetic retinoids as inducers of apoptosis in ovarian carcinoma cell lines,” Journal of Cellular Physiology, vol. 199, no. 3, pp. 317–329, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. V. Appierto, P. Tiberio, E. Cavadini, P. Casalini, G. Cappelletti, and F. Formelli, “Antimitotic effect of the retinoid 4-oxo-fenretinide through inhibition of tubulin polymerization: a novel mechanism of retinoid growth-inhibitory activity,” Molecular Cancer Therapeutics, vol. 8, no. 12, pp. 3360–3368, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. N. Oridate, S. Suzuki, M. Higuchi, M. F. Mitchell, W. K. Hong, and R. Lotan, “Involvement of reactive oxygen species in N-(4- hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells,” Journal of the National Cancer Institute, vol. 89, no. 16, pp. 1191–1198, 1997. View at Google Scholar · View at Scopus
  27. D. Delia, A. Aiello, L. Meroni, M. Nicolini, J. C. Reed, and M. A. Pierotti, “Role of antioxidants and intracellular free radicals in retinamide-induced cell death,” Carcinogenesis, vol. 18, no. 5, pp. 943–948, 1997. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Tosetti, R. Venè, G. Arena et al., “N-(4-hydroxyphenyl)retinamide inhibits retinoblastoma growth through reactive oxygen species-mediated cell death,” Molecular Pharmacology, vol. 63, no. 3, pp. 565–573, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. B. J. Maurer, L. Melton, C. Billups, M. C. Cabot, and C. P. Reynolds, “Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism,” Journal of the National Cancer Institute, vol. 92, no. 23, pp. 1897–1909, 2000. View at Google Scholar · View at Scopus
  30. M. B. Sporn, N. M. Dunlop, D. L. Newton, and J. M. Smith, “Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids),” Federation Proceedings, vol. 35, no. 6, pp. 1332–1338, 1976. View at Google Scholar · View at Scopus
  31. R. C. Moon, H. J. Thompson, P. J. Becci et al., “N-(4-hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat,” Cancer Research, vol. 39, no. 4, pp. 1339–1346, 1979. View at Google Scholar
  32. G. J. Kelloff, J. A. Crowell, C. W. Boone et al., “Clinical development plan: N-(4-hydroxyphenyl)retinamide,” Journal of cellular biochemistry. Supplement, vol. 20, pp. 176–196, 1994. View at Google Scholar · View at Scopus
  33. R. G. Mehta, R. C. Moon, M. Hawthorne, F. Formelli, and A. Costa, “Distribution of fenretinide in the mammary gland of breast cancer patients,” European Journal of Cancer, vol. 27, no. 2, pp. 138–141, 1991. View at Publisher · View at Google Scholar · View at Scopus
  34. J. S. Chapman, K. L. Weiss, R. W. Curley Jr., M. A. Highland, and M. Clagett-Dame, “Hydrolysis of 4-HPR to atRA occurs in vivo but is not required for retinamide-induced apoptosis,” Archives of Biochemistry and Biophysics, vol. 419, no. 2, pp. 234–243, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. C. P. Reynolds, K. K. Matthay, J. G. Villablanca, and B. J. Maurer, “Retinoid therapy of high-risk neuroblastoma,” Cancer Letters, vol. 197, no. 1-2, pp. 185–192, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. P. H. O'Donnell, W. X. Guo, C. P. Reynolds, and B. J. Maurer, “N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes,” Leukemia, vol. 16, no. 5, pp. 902–910, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. S. Batra, C. P. Reynolds, and B. J. Maurer, “Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators,” Cancer Research, vol. 64, no. 15, pp. 5415–5424, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. A. Costa, W. Malone, M. Perloff et al., “Tolerability of the synthetic retinoid fenretinide® (HPR),” European Journal of Cancer and Clinical Oncology, vol. 25, no. 5, pp. 805–808, 1989. View at Google Scholar · View at Scopus
  39. F. Formelli, R. Carsana, A. Costa et al., “Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients,” Cancer Research, vol. 49, no. 21, pp. 6149–6152, 1989. View at Google Scholar · View at Scopus
  40. U. Veronesi, G. de Palo, E. Marubini et al., “Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer,” Journal of the National Cancer Institute, vol. 91, no. 21, pp. 1847–1856, 1999. View at Google Scholar · View at Scopus
  41. U. Veronesi, L. Mariani, A. Decensi et al., “Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer,” Annals of Oncology, vol. 17, no. 7, pp. 1065–1071, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. A. M. Simeone, C. X. Deng, G. J. Kelloff, V. E. Steele, M. M. Johnson, and A. M. Tari, “N-(4-hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells,” Carcinogenesis, vol. 26, no. 5, pp. 1000–1007, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. R. Baserga, “The insulin-like growth factor I receptor: a key to tumor growth?” Cancer Research, vol. 55, no. 2, pp. 249–252, 1995. View at Google Scholar · View at Scopus
  44. S. E. Hankinson, W. C. Willett, G. A. Colditz et al., “Circulating concentrations of insulin-like growth factor-I and risk of breast cancer,” Lancet, vol. 351, no. 9113, pp. 1393–1396, 1998. View at Publisher · View at Google Scholar · View at Scopus
  45. J. M. Chan, M. J. Stampfer, E. Giovannucci et al., “Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study,” Science, vol. 279, no. 5350, pp. 563–566, 1998. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Yu, M. R. Spitz, J. Mistry, J. Gu, W. K. Hong, and X. Wu, “Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis,” Journal of the National Cancer Institute, vol. 91, no. 2, pp. 151–156, 1999. View at Google Scholar · View at Scopus
  47. J. Ma, M. N. Pollak, E. Giovannucci et al., “Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3,” Journal of the National Cancer Institute, vol. 91, no. 7, pp. 620–625, 1999. View at Google Scholar · View at Scopus
  48. R. E. Favoni, A. de Cupis, S. Bruno et al., “Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines,” British Journal of Cancer, vol. 77, no. 12, pp. 2138–2147, 1998. View at Google Scholar · View at Scopus
  49. R. Torrisi, F. Pensa, M. A. Orengo et al., “The synthetic retinoid fenretinide lowers plasma insulin-like growth factor-I levels in breast cancer patients,” Cancer Research, vol. 53, no. 20, pp. 4769–4771, 1993. View at Google Scholar · View at Scopus
  50. A. M. Simeone, Y. J. Li, L. D. Broemeling, M. M. Johnson, M. Tuna, and A. M. Tari, “Cyclooxygenase-2 Is Essential for HER2/neu to Suppress N-(4-Hydroxyphenyl)retinamide apoptotic effects in breast cancer cells,” Cancer Research, vol. 64, no. 4, pp. 1224–1228, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. T. Camerini, L. Mariani, G. de Palo et al., “Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer,” Journal of Clinical Oncology, vol. 19, no. 6, pp. 1664–1670, 2001. View at Google Scholar · View at Scopus
  52. A. Decensi, R. Torrisi, A. Gozza et al., “Effect of fenretinide on bone mineral density and metabolism in women with early breast cancer,” Breast Cancer Research and Treatment, vol. 53, no. 2, pp. 145–151, 1999. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Zujewski, L. Pai, L. Wakefield et al., “Tamoxifen and fenretinide in women with metastatic breast cancer,” Breast Cancer Research and Treatment, vol. 57, no. 3, pp. 277–283, 1999. View at Publisher · View at Google Scholar · View at Scopus
  54. M. A. Cobleigh, K. Dowlatshahi, T. A. Deutsch et al., “Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer,” Journal of Clinical Oncology, vol. 11, no. 3, pp. 474–477, 1993. View at Google Scholar · View at Scopus
  55. D. R. Doose, F. L. Minn, S. Stellar, and R. K. Nayak, “Effects of meals and meal composition on the bioavailability of fenretinide,” Journal of Clinical Pharmacology, vol. 32, no. 12, pp. 1089–1095, 1992. View at Google Scholar · View at Scopus
  56. F. Formelli, M. Clerici, T. Campa et al., “Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations,” Journal of Clinical Oncology, vol. 11, no. 10, pp. 2036–2042, 1993. View at Google Scholar · View at Scopus
  57. Y. M. Peng, W. S. Dalton, D. S. Alberts, M. J. Xu, H. Lim, and F. L. Meyskens, “Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients,” International Journal of Cancer, vol. 43, no. 1, pp. 22–26, 1989. View at Google Scholar · View at Scopus
  58. T. A. Ratko, C. J. Detrisac, N. M. Dinger, C. F. Thomas, G. J. Kelloff, and R. C. Moon, “Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats,” Cancer Research, vol. 49, no. 16, pp. 4472–4476, 1989. View at Google Scholar · View at Scopus
  59. B. Conley, J. O'Shaughnessy, S. Prindiville et al., “Pilot trial of the safety, tolerability, and retinoid levels of N-(4- hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer,” Journal of Clinical Oncology, vol. 18, no. 2, pp. 275–283, 2000. View at Google Scholar · View at Scopus
  60. A. Decensi, C. Robertson, A. Guerrieri-Gonzaga et al., “Randomized double-blind 2 X 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women,” Journal of Clinical Oncology, vol. 27, no. 23, pp. 3749–3756, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. A. Decensi, B. Bonanni, L. Baglietto et al., “A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers,” Clinical Cancer Research, vol. 10, no. 13, pp. 4389–4397, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. G. de Palo, U. Veronesi, T. Camerini et al., “Can fenretinide protect women against ovarian cancer?” Journal of the National Cancer Institute, vol. 87, no. 2, pp. 146–147, 1995. View at Google Scholar · View at Scopus
  63. G. de Palo, L. Mariani, T. Camerini et al., “Effect of fenretinide on ovarian carcinoma occurrence,” Gynecologic Oncology, vol. 86, no. 1, pp. 24–27, 2002. View at Publisher · View at Google Scholar · View at Scopus